The offering is now closed and shares are trading. Expect near-term price pressure from the dilutive issuance and potential overhang from the warrants (exercisable at $17.825 and $19.375). Monitor for use of proceeds updates and pipeline catalysts for paxalisib that could trigger warrant exercise milestones. The $37.2M net proceeds extend the cash runway but at the cost of significant shareholder dilution.
Price Chart
Executive Summary
Kazia Therapeutics filed the underwriting agreement for its previously announced public offering of 2,276,800 ADSs, pre-funded warrants for 303,200 ADSs, Series A warrants (2,243,478) at $17.825 exercise price, and Series B warrants (2,064,000) at $19.375 exercise price. Gross proceeds total approximately $40M, net proceeds ~$37.2M after underwriting discounts. The offering was priced at $15.50 per ADS unit, below the prior close of $16.90, and represents roughly 26% dilution relative to the $155M market cap. This 6-K confirms the closing of the capital raise, which is a material dilutive event for existing shareholders.
Key Facts
- Offering of 2,276,800 ADSs at $15.50 per ADS unit, plus 303,200 pre-funded warrants at $15.4999, with Series A warrants (2,243,478 at $17.825) and Series B warrants (2,064,000 at $19.375)
- Total gross proceeds approximately $39,989,969; net proceeds to company approximately $37,190,669 after $2,799,300 in underwriting discounts
- Offering price of $15.50 represents a discount to the last reported sale price of $16.90 on August 27, 2026
- Series A and B warrants have exercise prices at 115% and 125% of the offering price, respectively, and expire upon achievement of clinical milestones for paxalisib or five years
- The offering closed on August 31, 2026, with Leerink Partners and Guggenheim Securities as joint bookrunners
Financial Impact
Approximately $40M gross capital raise, representing ~26% dilution of the $155M market cap; net proceeds of ~$37.2M will fund operations
Risk Factors
- Immediate dilution of ~26% from the ADS and pre-funded warrant issuance
- Warrant overhang: up to 4.3M additional ADSs issuable if Series A and B warrants are exercised, further diluting shareholders
- Stock price may face selling pressure as investors digest the discounted offering
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-095310 |
| Document: ea030382001ex10-3.htm | 0001213900-26-095310 |
| Document: ea030382001ex10-2.htm | 0001213900-26-095310 |
| Document: ea030382001ex10-1.htm | 0001213900-26-095310 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $7.87 (−15.10%) |
Sep 22, 2026 4w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $7.87 (−27.93%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $7.87 (−37.59%) |
Aug 31, 2026 7w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $7.87 (+37.69%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $7.87 (−42.85%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $7.87 (+42.05%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $7.87 (−42.05%) |
Jul 28, 2026 12w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $7.87 (−37.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers